Get the Stockscreener App
3.70
11.11%
0.37
Pre-market:
3.64
-0.06
-1.62%
Minerva Neurosciences Inc stock is traded at $3.70, with a volume of 30,156.
It is up +11.11% in the last 24 hours and up +0.82% over the past month.
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
See More
Previous Close:
$3.33
Open:
$3.27
24h Volume:
30,156
Relative Volume:
0.01
Market Cap:
$25.88M
Revenue:
-
Net Income/Loss:
$-33.65M
P/E Ratio:
-0.8315
EPS:
-4.45
Net Cash Flow:
$-20.83M
1W Performance:
-2.12%
1M Performance:
+0.82%
6M Performance:
+100.00%
1Y Performance:
+68.95%
1-Day Range:
$3.27
$3.72
1-Week Range:
$3.25
$4.205
52-Week Range:
$1.15
$12.46
Minerva Neurosciences Inc Stock (NERV) Company Profile
Name
Minerva Neurosciences Inc
Sector
Industry
Phone
617-600-7373
Address
1500 DISTRICT AVENUE, BURLINGTON, MA
Compare NERV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NERV
Minerva Neurosciences Inc
|
3.70 | 23.29M | 0 | -33.65M | -20.83M | -4.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Minerva Neurosciences Inc Stock (NERV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-08-20 | Reiterated | H.C. Wainwright | Buy |
| May-14-20 | Initiated | BTIG Research | Buy |
| Oct-02-19 | Reiterated | Chardan Capital Markets | Buy |
| Sep-25-19 | Initiated | Chardan Capital Markets | Buy |
| Sep-18-19 | Initiated | William Blair | Outperform |
| May-31-19 | Initiated | H.C. Wainwright | Buy |
| Sep-01-17 | Initiated | Citigroup | Buy |
| Mar-06-17 | Resumed | Jefferies | Buy |
| May-12-16 | Resumed | Jefferies | Buy |
View All
Minerva Neurosciences Inc Stock (NERV) Latest News
Is Minerva Neurosciences Inc. stock a buy for dividend growth2025 EndofYear Setup & Safe Entry Zone Tips - Newser
How risky is Minerva Neurosciences Inc. (4MNA) stock compared to peersPortfolio Performance Report & Long Hold Capital Preservation Plans - Newser
How Minerva Neurosciences Inc. stock reacts to oil prices2025 Top Decliners & Technical Pattern Recognition Alerts - Newser
Minerva jumps on phase III funding, leading neuro stocks - BioWorld MedTech
Is Minerva Neurosciences Inc. stock attractive for retirement portfolios2025 Earnings Surprises & Capital Efficiency Focused Strategies - Newser
Will Minerva Neurosciences Inc. (4MNA) stock boost dividends furtherSell Signal & Fast Exit and Entry Strategy Plans - Newser
Is Minerva Neurosciences Inc. (4MNA) stock cheap vs fundamentalsJuly 2025 Action & Verified Swing Trading Watchlist - Newser
How Minerva Neurosciences Inc. (4MNA) stock compares with tech leadersJuly 2025 Weekly Recap & Stock Portfolio Risk Control - Newser
Market Fear: Why Minerva Neurosciences Inc 4MNA stock stays resilientJuly 2025 Outlook & Capital Efficiency Focused Ideas - BỘ NỘI VỤ
How Minerva Neurosciences Inc. stock trades during market volatilityJuly 2025 Catalysts & Free Low Drawdown Momentum Trade Ideas - BỘ NỘI VỤ
Performance Recap: What risks investors should watch in Minerva Neurosciences Inc. stock2025 Market Trends & Consistent Return Strategy Ideas - BỘ NỘI VỤ
Minerva Neurosciences Inc (NERV) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
What risks investors should watch in Minerva Neurosciences Inc. stock2025 Technical Overview & Low Risk Profit Maximizing Plans - moha.gov.vn
Why analysts upgrade Minerva Neurosciences Inc. stockJuly 2025 Opening Moves & Long Hold Capital Preservation Tips - BỘ NỘI VỤ
Contrasting Minerva Neurosciences (NASDAQ:NERV) and Madrigal Pharmaceuticals (NASDAQ:MDGL) - Defense World
What analysts say about Minerva Neurosciences Inc 4MNA stockStraddle and Strangle Trades & Superior Wealth Growth - earlytimes.in
Why Minerva Neurosciences Inc. stock appeals to analysts2025 Major Catalysts & Fast Gain Swing Trade Alerts - newser.com
Why Minerva Neurosciences Inc. (4MNA) stock attracts wealthy investorsPortfolio Growth Summary & High Conviction Buy Zone Picks - newser.com
Using Ichimoku Cloud for Minerva Neurosciences Inc. technicalsMarket Movers & Accurate Buy Signal Notifications - newser.com
Minerva Neurosciences Expands Board Amid Fundraising Effort - The Globe and Mail
Multi asset correlation models including Minerva Neurosciences Inc.July 2025 Big Picture & Weekly Top Gainers Alerts - newser.com
What to do if you’re stuck in Minerva Neurosciences Inc.Trade Signal Summary & Safe Capital Investment Plans - newser.com
Is Minerva Neurosciences Inc. stock vulnerable to regulatory risksForecast Cut & AI Forecast for Swing Trade Picks - newser.com
How buybacks impact Minerva Neurosciences Inc. stock valueEarnings Performance Report & Daily Oversold Stock Bounce Ideas - newser.com
Minerva Neurosciences appoints schizophrenia expert to board of directors By Investing.com - Investing.com Nigeria
Regression analysis insights on Minerva Neurosciences Inc. performance2025 Winners & Losers & Low Risk Entry Point Guides - newser.com
Will Minerva Neurosciences Inc. stock sustain high P E ratiosJuly 2025 Levels & Risk Controlled Daily Plans - newser.com
Is Minerva Neurosciences Inc. stock ready for a breakout2025 Technical Patterns & Long-Term Safe Investment Plans - newser.com
Minerva Neurosciences Appoints Dr. Inderjit Kaul To Board - citybiz
Minerva Neurosciences appoints Dr. Inderjit Kaul to the company's board of directors - MarketScreener
Minerva Neurosciences Appoints Dr. Inderjit Kaul To The Company’S Board Of Directors - TradingView
Minerva Neurosciences Appoints Dr. Inderjit Kaul to Board of Directors as Company Advances Clinical Development of Roluperidone for Schizophrenia Treatment - Quiver Quantitative
Minerva Neurosciences appoints schizophrenia expert to board of directors - Investing.com India
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors - The Manila Times
Is Minerva Neurosciences Inc. stock overvalued by current metricsJuly 2025 Analyst Calls & Real-Time Volume Spike Alerts - newser.com
Will Minerva Neurosciences Inc. (4MNA) stock extend growth storyJuly 2025 Big Picture & Risk Managed Investment Entry Signals - newser.com
Visual analytics tools that track Minerva Neurosciences Inc. performanceJuly 2025 Opening Moves & Reliable Trade Execution Plans - newser.com
Automated trading signals detected on Minerva Neurosciences Inc.Weekly Market Summary & Comprehensive Market Scan Insights - newser.com
Why Minerva Neurosciences Inc. stock is seen as undervaluedMarket Trend Summary & Smart Allocation Stock Tips - newser.com
Minerva Neurosciences Inc Stock (NERV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):